Dimitrios E Magouliotis1, Kostas Lafazanis2, Fani Koutsougianni2, Nikos Sakellaridis2, Maria Ioannou3, Dimitris Zacharoulis4, Konstantinos Dimas5. 1. Department of Cardiothoracic Surgery, University of Thessaly, Biopolis, Larissa, Greece. 2. Department of Pharmacology, University of Thessaly, Biopolis, Larissa, Greece. 3. Department of Pathology, University of Thessaly, Biopolis, Larissa, Greece. 4. Department of Surgery, University of Thessaly, Biopolis, Larissa, Greece. 5. Department of Pharmacology, University of Thessaly, Biopolis, Larissa, Greece; kdimas@uth.gr.
Abstract
BACKGROUND/AIM: Pancreatic cancer (PC) is one of the leading causes of cancer-related death. The purpose of the present study was to establish a patient-derived orthotopic xenograft model (PDOX) for pancreatic ductal adenocarcinoma (PDAC), thus providing a tumor microenvironment resembling that of the human pancreas to identify novel potential biomarkers and treatment regimens. MATERIALS AND METHODS: PDAC tissue samples were received from 35 patients, following informed consent, and three mouse strains were implemented. RESULTS: Successful PDOX engraftment was performed in nonobese diabetic/severe combined immunodeficient (NOD/SCID) and NOD/SCID gamma (NSG) mice. Nonetheless, we found a higher rate of successful engraftment and tumor growth in NSG compared to NOD/SCID mice, possibly owning to the different level of immunosuppression and more specifically of the natural killer cells presence. CONCLUSION: Our suggested PDOX model represents a preclinical cancer research model with a high affinity for the patient's tumor microenvironment, thus enabling the acceleration of PDAC research.
BACKGROUND/AIM: Pancreatic cancer (PC) is one of the leading causes of cancer-related death. The purpose of the present study was to establish a patient-derived orthotopic xenograft model (PDOX) for pancreatic ductal adenocarcinoma (PDAC), thus providing a tumor microenvironment resembling that of the human pancreas to identify novel potential biomarkers and treatment regimens. MATERIALS AND METHODS: PDAC tissue samples were received from 35 patients, following informed consent, and three mouse strains were implemented. RESULTS: Successful PDOX engraftment was performed in nonobese diabetic/severe combined immunodeficient (NOD/SCID) and NOD/SCID gamma (NSG) mice. Nonetheless, we found a higher rate of successful engraftment and tumor growth in NSG compared to NOD/SCID mice, possibly owning to the different level of immunosuppression and more specifically of the natural killer cells presence. CONCLUSION: Our suggested PDOX model represents a preclinical cancer research model with a high affinity for the patient's tumor microenvironment, thus enabling the acceleration of PDAC research.
Authors: Eunsung Jun; Jaeyoon Jung; Seong-Yun Jeong; Eun Kyung Choi; Moon Bo Kim; Ji Sun Lee; Seung-Mo Hong; Hyang Sook Seol; Changmo Hwang; Robert M Hoffman; In Kyong Shim; Suhwan Chang; Song Cheol Kim Journal: Anticancer Res Date: 2016-02 Impact factor: 2.480
Authors: Nathaniel F Wu; Justin Wu; Jun Yamamoto; Yusuke Aoki; Chihiro Hozumi; Michael Bouvet; Robert M Hoffman Journal: In Vivo Date: 2021 Jul-Aug Impact factor: 2.155